Home Committee Nominations 2021-2023 IASLC Committee Nominations One of the unique benefits of an IASLC membership is the opportunity to serve on an IASLC committee in a volunteer capacity. IASLC committee members contribute their specialized skills and talents to help shape the work of the organization, develop educational content, shape the association’s messaging, plan annual…
2024 Texas Lung Cancer Conference Agenda @TLCconference #TexasLung24
Immune checkpoint inhibitor (ICI)’s targeting the programmed-death-1/programmed-death ligand 1 (PD-1/PD-L1) axis have established themselves as part of the first line management of metastatic non-small cell…
Responses to first-line PD-1 inhibition vary among patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 TPS ≥50%. We previously reported improved clinical…
For patients with KRASG12C-mutated NSCLC who are treated with sotorasib, there is a lack of biomarkers to guide treatment decisions. We therefore investigated the clinical…
One of the most frequent oncogenic event in non-small cell lung cancer (NSCLC) is a glycine to cysteine substitution in position 12 in the V-ki-ras2…
The deadline to submit nominations is April 12, 2024 at midnight MST. The IASLC Cancer Care Team Award honors multidisciplinary teams, as nominated by the…
The landscape of treatment options for patients with advanced non–small cell lung cancer continues to evolve rapidly, with the recently updated non–small cell lung cancer…
Immune checkpoint inhibitors (ICIs), including anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death protein–ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) antibodies, have…
Our assessment of cancer immunotherapies (CIT) randomized controlled trials (RCTs) published over the last two years in major journals (Appendix 2) reveals that knowledge of…
Abstract. Purpose: Current NCCN guidelines recommend afatinib or osimertinib as the preferred first-line treatment strategy for patients with advanced NSCLC harboring EGFR p.G719X mutation. However,…
